| Title |
Paclitaxel: new uses for an old drug
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2014
|
| DOI | 10.2147/dddt.s56801 |
| Pubmed ID | |
| Authors |
Dongshan Zhang, Ruhao Yang, Shixuan Wang, Zheng Dong |
| Abstract |
Paclitaxel (Taxol), one of the most important anticancer drugs, has been used for therapy of different types of cancers. Mechanistically, paclitaxel arrests cell cycle and induces cell death by stabilizing microtubules and interfering with microtubule disassembly in cell division. Recently, it has been found that low-dose paclitaxel seems promising in treating non-cancer diseases, such as skin disorders, renal and hepatic fibrosis, inflammation, axon regeneration, limb salvage, and coronary artery restenosis. Future studies need to understand the mechanisms underlying these effects in order to design therapies with specificity. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 197 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | <1% |
| Unknown | 196 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 30 | 15% |
| Student > Bachelor | 29 | 15% |
| Student > Ph. D. Student | 17 | 9% |
| Researcher | 11 | 6% |
| Student > Doctoral Student | 10 | 5% |
| Other | 30 | 15% |
| Unknown | 70 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 27 | 14% |
| Agricultural and Biological Sciences | 23 | 12% |
| Medicine and Dentistry | 21 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 9% |
| Chemistry | 12 | 6% |
| Other | 25 | 13% |
| Unknown | 72 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2014.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#1,299
of 2,254 outputs
Outputs of similar age
#236,429
of 323,682 outputs
Outputs of similar age from Drug Design, Development and Therapy
#12
of 21 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,682 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.